Evidence map›Paper›PMID 40317973›Full record

ArticleAllergy2025

Clinical Characteristics of Difficult-To-Treat Allergic Bronchopulmonary Aspergillosis and Its Prediction Score.

Jun Tanaka, Tsuyoshi Oguma, Takashi Ishiguro, Hirokazu Taniguchi, Teruaki Nishiuma, Hiroki Tateno, Hisako Matsumoto, Naoki Koshimizu, Yutaka Ito, Kazuto Matsunaga and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jun TanakaDivision of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Tsuyoshi OgumaDivision of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Takashi IshiguroDepartment of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, Japan.
Hirokazu TaniguchiDivision of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Japan.
Teruaki NishiumaDepartment of Respiratory Medicine, Kakogawa Central City Hospital, Kakogawa, Japan.ORCID https://orcid.org/0000-0001-9390-8031
Hiroki TatenoDepartment of Pulmonary Medicine, Saitama City Hospital, Saitama, Japan.
Hisako MatsumotoDepartment of Respiratory Medicine and Allergology, Kindai University School of Medicine, Osaka, Japan.
Naoki KoshimizuDivision of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan.
Yutaka ItoDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Kazuto MatsunagaDepartment of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube, Japan.
Hidekazu MatsushimaDepartment of Respiratory Medicine, Saitama Red Cross Hospital, Saitama, Japan.
Yoshitaka UchidaDepartment of Respiratory Medicine, Saitama Medical University Hospital, Saitama, Japan.ORCID https://orcid.org/0000-0001-8562-707X
Koshi YokomuraDivision of Respiratory Medicine, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Hirotaka YasubaDepartment of Airway Medicine, Mitsubishi Kyoto Hospital, Kyoto, Japan.
Junko SuzukiDepartment of Respiratory Medicine, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
Shigeaki HattoriDivision of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Naoki OkadaDivision of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Katsuyoshi TomomatsuDivision of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Koichiro AsanoDivision of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
ABPM Research Program

Funding

Japan Agency for Medical Research and Development
6 · The paper itself

Abstract

BACKGROUND AND

objectiveAdministration of oral corticosteroids and/or azole antifungals for 4-6 months remains the standard treatment for allergic bronchopulmonary aspergillosis (ABPA). This study investigated the clinical characteristics of patients with difficult-to-treat ABPA who failed to achieve clinical remission within 6 months.

methodsAmong the participants of a nationwide survey conducted in Japan in 2020, treatment-naïve patients with ABPA who satisfied Asano's criteria were enrolled in this study. Clinical remission was defined as stable disease without exacerbation for ≥ 6 months under minimal treatment (oral prednisolone: ≤ 5 mg/day and no antifungal medication). A risk prediction score for difficult-to-treat ABPA was developed and validated in an independent cohort comprising patients with ABPA from a prospective registration study in Japan.

resultsIn total, 316 treatment-naïve patients with ABPA were enrolled in the study. The median time to minimal treatment status was 4.8 months in the group receiving standard treatment. The clinical remission rate at 6 months after standard treatment was 51%. Age ≤ 50 years at onset of ABPA (p = 0.04), serum A. fumigatus-specific IgE titer of ≥ 20 U

conclusionMultiple components, including age at onset, allergic sensitization, airway fungal burden, and HAM, were associated with difficult-to-treat ABPA.

Indexed as

Antifungal AgentsAspergillosis, Allergic BronchopulmonaryAdultAgedFemaleHumansImmunoglobulin EJapanMaleMiddle AgedPrognosisProspective StudiesTreatment OutcomeAntifungal AgentsImmunoglobulin Eallergic bronchopulmonary aspergillosisAspergillus fumigatusclinical remissionexacerbationimmunoglobulin E

Identifiers

PMID40317973
PMCPMC12444840

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.